41521
document
Sustained benefit of continuous glucose monitoring on A1C , glucose profiles , and hypoglycemia in adults with type 1 diabetes . OBJECTIVE To evaluate long-term effects of continuous glucose monitoring ( CGM ) in intensively treated adults with type 1 diabetes . RESEARCH DESIGN AND METHODS We studied 83 of 86 individuals > or=25 years of age with type 1 diabetes who used CGM as part of a 6-month randomized clinical trial in a subsequent 6-month extension study . RESULTS After 12 months , median CGM use was 6.8 days per week . Mean change in A1C level from baseline to 12 months was -0.4 +/- 0.6 % ( P < 0.001 ) in subjects with baseline A1C > or=7.0 % . A1C remained stable at 6.4 % in those with baseline A1C < 7.0 % . The incidence rate of severe hypoglycemia was 21.8 and 7.1 events per 100 person-years in the first and last 6 months , respectively . Time per day with glucose levels in the range of 71-180 mg/dl increased significantly ( P = 0.02 ) from baseline to 12 months . CONCLUSIONS In intensively treated adults with type 1 diabetes , CGM use and benefit can be sustained for 12 months .
41522
Intervention_Educational
continuous glucose monitoring ( CGM )
41523
Outcome_Physical
Mean change in A1C level
41524
Outcome_Physical
A1C
41525
Outcome_Physical
incidence rate of severe hypoglycemia
41526
Outcome_Physical
Time per day with glucose levels
41527
Participant_Age
adults
41528
Participant_Condition
type 1 diabetes
41529
Participant_Age
intensively treated adults
41530
Participant_Condition
type 1 diabetes
41531
Participant_Age
83 of 86 individuals > or=25 years of age with type 1 diabetes who used CGM as part of a 6-month randomized clinical trial in a subsequent 6-month extension study .
41532
Participant_Age
adults
41533
Participant_Condition
type 1 diabetes